1
|
Arao Y, Hamilton KJ, Grimm SA, Korach KS. The genomic regulatory elements for estrogen receptor alpha transactivation-function-1 regulated genes. FASEB J 2020; 34:16003-16021. [PMID: 33064339 DOI: 10.1096/fj.202001435r] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 09/02/2020] [Accepted: 09/24/2020] [Indexed: 01/24/2023]
Abstract
Estrogen receptor alpha (ERα) is a ligand-dependent transcription regulator, containing two transactivation functional domains, AF-1 and AF-2. The selective estrogen receptor modulators (SERMs), including 4-hydroxytamoxifen (4OHT), activate AF-1 preferentially rather than AF-2. However, it is unclear whether this specific function is related to the tissue-selective functionality of SERMs. Moreover, there is no information determining AF-1-dependent estrogenic-genes existing in tissues. We sought to identify AF-1-dependent estrogenic-genes using the AF-2 mutated knock-in (KI) mouse model, AF2ERKI. AF2ER is an AF-2 disrupted estradiol (E2)-insensitive mutant ERα, but AF-1-dependent transcription can be activated by the estrogen-antagonists, fulvestrant (ICI) and 4OHT. Gene profiling and ChIP-Seq analysis identified Klk1b21 as an ICI-inducible gene in AF2ERKI uterus. The regulatory activity was analyzed further using a cell-based reporter assay. The 5'-flanking 0.4k bp region of Klk1b21 gene responded as an ERα AF-1-dependent estrogen-responsive promoter. The 150 bp minimum ERα binding element (EBE) consists of three direct repeats. These three half-site sequences were essential for the ERα-dependent transactivation and were differentially recognized by E2 and 4OHT for the gene activation. This response was impaired when the minimum EBE was fused with a thymidine-kinase promoter but could be restored by fusion with the 100 bp minimum transcription initiation element (TIE) of Klk1b21, suggesting that the cooperative function of EBE and TIE is essential for mediating AF-1-dependent transactivation. These findings provide the first in vivo evidence that endogenous ERα AF-1 dominant estrogenic-genes exist in estrogen-responsive organs. Such findings will aid in understanding the mechanism of ERα-dependent tissue-selective activity of SERMs.
Collapse
Affiliation(s)
- Yukitomo Arao
- Receptor Biology Section, Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, NC, USA
| | - Katherine J Hamilton
- Receptor Biology Section, Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, NC, USA
| | - Sara A Grimm
- Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, NC, USA
| | - Kenneth S Korach
- Receptor Biology Section, Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, NC, USA
| |
Collapse
|
2
|
Helle J, Keiler AM, Zierau O, Dörfelt P, Vollmer G, Lehmann L, Chittur SV, Tenniswood M, Welsh J, Kretzschmar G. Effects of the aryl hydrocarbon receptor agonist 3-methylcholanthrene on the 17β-estradiol regulated mRNA transcriptome of the rat uterus. J Steroid Biochem Mol Biol 2017; 171:133-143. [PMID: 28285017 DOI: 10.1016/j.jsbmb.2017.03.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2016] [Revised: 03/01/2017] [Accepted: 03/06/2017] [Indexed: 10/20/2022]
Abstract
Polycyclic aromatic hydrocarbons (PAHs) are products of incomplete combustion of organic compounds, abundant in exhaust fumes and cigarette smoke. They act by binding to the aryl hydrocarbon receptor (AHR) which induces expression of phase 1 and phase 2 enzymes in the liver. PAH induced AHR activation may also lead to adverse effects by modulating other pathways, for example estrogen receptor (ER) signaling in the female reproductive tract. We have investigated the effects of the PAH 3-methylcholanthrene (3-MC) on 17β-estradiol (E2) dependent signaling in the uterus of ovariectomized rats to characterize the cross talk between AHR and ER on an mRNA transcriptome wide scale. A standard three day uterotrophic assay was performed in young adult Lewis rats. Treatment induced effects were analyzed using histology, immunohistochemistry and gene expression analysis by microarray and qPCR. 3-MC shows broad E2 antagonistic effects on uterine mRNA transcription of the vast majority of E2 regulated genes, significantly altering prostaglandin biosynthesis, complement activation, coagulation pathways and other inflammatory response pathways. The regulation of ER expression in the uterus, but not the regulation of E2 metabolism in the liver, was identified as a potentially important factor in mediating this general antiestrogenic effect. The regulation of prostaglandin biosynthesis by E2 is important for inflammation-like events during pregnancy including the initiation of birth. Our results suggest that adverse effects of PAHs on prostaglandin related pathways are likely caused by the interference with E2 signaling, specifically by inhibiting the E2 mediated downregulation of PGF2α. Characterization of the generalized antagonistic effect of 3-MC on E2 dependent signaling in the rat uterus thus contributes to a better understanding of molecular mechanisms of the toxicity of PAHs in female reproductive organs.
Collapse
Affiliation(s)
- Janina Helle
- Institute of Zoology, Molecular Cell Physiology and Endocrinology, Technische Universität Dresden, 01062, Dresden, Germany
| | - Annekathrin M Keiler
- Institute of Zoology, Molecular Cell Physiology and Endocrinology, Technische Universität Dresden, 01062, Dresden, Germany
| | - Oliver Zierau
- Institute of Zoology, Molecular Cell Physiology and Endocrinology, Technische Universität Dresden, 01062, Dresden, Germany
| | - Peggy Dörfelt
- Institute of Zoology, Molecular Cell Physiology and Endocrinology, Technische Universität Dresden, 01062, Dresden, Germany
| | - Günter Vollmer
- Institute of Zoology, Molecular Cell Physiology and Endocrinology, Technische Universität Dresden, 01062, Dresden, Germany
| | - Leane Lehmann
- Institute of Pharmacy and Food Chemistry, Universität Würzburg, 97070 Würzburg, Germany
| | - Sridar V Chittur
- Cancer Research Center and Department of Biomedical Sciences, University at Albany, NY 12144-2345, United States
| | - Martin Tenniswood
- Cancer Research Center and Department of Biomedical Sciences, University at Albany, NY 12144-2345, United States
| | - JoEllen Welsh
- Cancer Research Center and Department of Biomedical Sciences, University at Albany, NY 12144-2345, United States
| | - Georg Kretzschmar
- Institute of Zoology, Molecular Cell Physiology and Endocrinology, Technische Universität Dresden, 01062, Dresden, Germany.
| |
Collapse
|
3
|
Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, Börjesson AE, Ohlsson C. Sex steroid actions in male bone. Endocr Rev 2014; 35:906-60. [PMID: 25202834 PMCID: PMC4234776 DOI: 10.1210/er.2014-1024] [Citation(s) in RCA: 184] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Sex steroids are chief regulators of gender differences in the skeleton, and male gender is one of the strongest protective factors against osteoporotic fractures. This advantage in bone strength relies mainly on greater cortical bone expansion during pubertal peak bone mass acquisition and superior skeletal maintenance during aging. During both these phases, estrogens acting via estrogen receptor-α in osteoblast lineage cells are crucial for male cortical and trabecular bone, as evident from conditional genetic mouse models, epidemiological studies, rare genetic conditions, genome-wide meta-analyses, and recent interventional trials. Genetic mouse models have also demonstrated a direct role for androgens independent of aromatization on trabecular bone via the androgen receptor in osteoblasts and osteocytes, although the target cell for their key effects on periosteal bone formation remains elusive. Low serum estradiol predicts incident fractures, but the highest risk occurs in men with additionally low T and high SHBG. Still, the possible clinical utility of serum sex steroids for fracture prediction is unknown. It is likely that sex steroid actions on male bone metabolism rely also on extraskeletal mechanisms and cross talk with other signaling pathways. We propose that estrogens influence fracture risk in aging men via direct effects on bone, whereas androgens exert an additional antifracture effect mainly via extraskeletal parameters such as muscle mass and propensity to fall. Given the demographic trends of increased longevity and consequent rise of osteoporosis, an increased understanding of how sex steroids influence male bone health remains a high research priority.
Collapse
Affiliation(s)
- Dirk Vanderschueren
- Clinical and Experimental Endocrinology (D.V.) and Gerontology and Geriatrics (M.R.L., E.G.), Department of Clinical and Experimental Medicine; Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine (M.R.L., F.C.); and Centre for Metabolic Bone Diseases (D.V., M.R.L., E.G.), KU Leuven, B-3000 Leuven, Belgium; and Center for Bone and Arthritis Research (M.K.L., L.V., A.E.B., C.O.), Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Murata T, Narita K, Ichimaru T. Rat uterine oxytocin receptor and estrogen receptor α and β mRNA levels are regulated by estrogen through multiple estrogen receptors. J Reprod Dev 2013; 60:55-61. [PMID: 24334513 PMCID: PMC3963296 DOI: 10.1262/jrd.2012-139] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Estrogen action is mediated through several types of receptors (ERs), such as ERα, ERβ
and putative membrane ERs. Oxytocin receptor (OTR) and ER expression levels in the rat
uterus are regulated by estrogen; however, which types of ERs are involved has not been
elucidated. This study examined OTR, ERα and ERβ levels in ovariectomized rats treated
with 17β-estradiol (E2), an ERα agonist (PPT), an ERβ agonist (DPN) or estren (Es). E2 and
PPT increased OTR mRNA levels and decreased ERα and ERβ mRNA levels 3 and 6 h
posttreatment. DPN decreased ERα and ERβ mRNA levels at 3 and 6 h, while OTR mRNA levels
increased at 3 h and decreased at 6 h. OTR mRNA levels increased 3 h after the Es
treatment and then declined until 6 h. ERα and ERβ mRNA levels decreased by 3 h and
remained low until 6 h posttreatment with Es. The ER antagonist ICI182,780 (ICI)
suppressed the increases in OTR mRNA levels induced 3 h after the Es treatment. However,
ICI and tamoxifen (Tam) had no significant effect on ERα and ERβ mRNA levels in the
Es-treated or vehicle-treated group. In intact rats, proestrus-associated increases in OTR
mRNA levels were antagonized by both ICI and Tam. However, decreases in ERα and ERβ mRNA
levels were not antagonized by Tam and ICI, respectively. Therefore, uterine OTR gene
expression is upregulated by estrogen through the classical nuclear (or non-nuclear) ERs,
ERα and ERβ, while the levels of these ERs are downregulated by estrogen through multiple
pathways including Es-sensitive nonclassical ERs.
Collapse
Affiliation(s)
- Takuya Murata
- Department of Integrative Physiology, Faculty of Medical Science, University of Fukui, Fukui 910-1193, Japan
| | | | | |
Collapse
|
5
|
Darlington Y, Jeong JW, Lee KY, Franco HL, Chen ES, McOwiti A, Mistretta TA, Steffen D, Becnel L, DeMayo FJ. Research Resource: The Endometrium Database Resource (EDR). Mol Endocrinol 2013; 27:548-54. [DOI: 10.1210/me.2012-1250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Abstract
In order to understand the biology of the endometrium and potentially develop new diagnostic tools and treatments for endometrial diseases, the highly orchestrated gene expression/regulation that occurs within the uterus must first be understood. Even though a wealth of information on endometrial gene expression/regulation is available, this information is scattered across several different resources in formats that can be difficult for the average bench scientist to query, integrate, and utilize. The Endometrium Database Resource (EDR) was created as a single evolving resource for protein- and micro-RNA-encoding genes that have been shown by gene expression microarray, Northern blot, or other experiments in the literature to have their expression regulated in the uterus of humans, mice, rats, cows, domestic pigs, guinea pigs, and sheep. Genes are annotated in EDR with basic gene information (eg, gene symbol and chromosome), gene orthologs, and gene ontologies. Links are also provided to external resources for publication/s, nucleic and amino acid sequence, gene product function, and Gene Expression Omnibus (GEO) phase expression graph information. The resource also allows for direct comparison of relative gene expression in different microarray experiments for genes shown in the literature to be differentially expressed in the uterus. It is available via a user-friendly, web-based interface and is available without charge or restriction to the entire scientific community. The EDR can be accessed at http://edr.research.bcm.edu.
Collapse
Affiliation(s)
- Yolanda Darlington
- Dan L. Duncan Cancer Center (Y.D., L.B.),Baylor College of Medicine, Houston, Texas 77030
| | - Jae-Wook Jeong
- Department of Molecular and Cellular Biology (J.-W.J., K.Y.L., H.L.F., L.B., F.J.D.),Baylor College of Medicine, Houston, Texas 77030
| | - Kevin Y. Lee
- Department of Molecular and Cellular Biology (J.-W.J., K.Y.L., H.L.F., L.B., F.J.D.),Baylor College of Medicine, Houston, Texas 77030
| | - Heather L. Franco
- Department of Molecular and Cellular Biology (J.-W.J., K.Y.L., H.L.F., L.B., F.J.D.),Baylor College of Medicine, Houston, Texas 77030
| | - Edward S. Chen
- Department of Medicine (E.S.C., A.M., T.-A.M., D.S., L.B., F.J.D.), Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas 77030
| | - Apollo McOwiti
- Department of Medicine (E.S.C., A.M., T.-A.M., D.S., L.B., F.J.D.), Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas 77030
| | - Toni-Ann Mistretta
- Department of Medicine (E.S.C., A.M., T.-A.M., D.S., L.B., F.J.D.), Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas 77030
| | - David Steffen
- Department of Medicine (E.S.C., A.M., T.-A.M., D.S., L.B., F.J.D.), Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas 77030
| | - Lauren Becnel
- Department of Molecular and Cellular Biology (J.-W.J., K.Y.L., H.L.F., L.B., F.J.D.),Baylor College of Medicine, Houston, Texas 77030
- Department of Medicine (E.S.C., A.M., T.-A.M., D.S., L.B., F.J.D.), Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas 77030
| | - Francesco J. DeMayo
- Department of Molecular and Cellular Biology (J.-W.J., K.Y.L., H.L.F., L.B., F.J.D.),Baylor College of Medicine, Houston, Texas 77030
- Department of Medicine (E.S.C., A.M., T.-A.M., D.S., L.B., F.J.D.), Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas 77030
| |
Collapse
|
6
|
Abstract
The sex steroid hormones, androgens and estrogens, via their respective nuclear receptors, regulate bone mineral density in humans and mice. Very little is known about the direct targets of the androgen and estrogen receptors in bone cells. First, models of hormone and receptor deficiency in mouse and human bone are discussed. This review then focuses on the direct targets of the receptors in osteoblasts and osteoclasts. A direct target of a NR is defined here as a gene that is regulated by NR binding to the DNA (either through DNA binding or association with a DNA binding protein) at an enhancer or promoter of that gene. The experimental evidence that illustrates androgen and estrogen gene regulation in osteoblasts and osteoclasts will be summarized and compared with the phenotype of the hormones in vivo.
Collapse
Affiliation(s)
- Susan A Krum
- Department of Orthopaedic Surgery, UCLA Orthopaedic Hospital, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
| |
Collapse
|
7
|
Hewitt SC, Korach KS. Estrogenic activity of bisphenol A and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE) demonstrated in mouse uterine gene profiles. ENVIRONMENTAL HEALTH PERSPECTIVES 2011; 119:63-70. [PMID: 20826375 PMCID: PMC3018502 DOI: 10.1289/ehp.1002347] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2010] [Accepted: 09/08/2010] [Indexed: 05/19/2023]
Abstract
BACKGROUND Interest and concern regarding potentially estrogenic substances have resulted in development of model systems to evaluate mechanisms of such chemicals. Microarray studies have indicated that estradiol (E2)-stimulated uterine responses can be divided into early and late phases. Comparison of E2 uterine transcript profiles and those of other estrogenic chemicals of interest in vivo indicates mechanisms and activities of test compounds. OBJECTIVES We compared transcript responses and mechanisms of response using mouse reproductive tracts after treatment with E2, estriol (E3), bisphenol A (BPA), and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE). METHODS Uterine RNA from ovariectomized wild-type mice, estrogen receptor α (ERα) knockout (αERKO) mice, and mice expressing a DNA-binding-deficient ERα (KIKO) treated with E2, E3, BPA, or HPTE for 2 or 24 hr was analyzed by microarray. Resulting regulated transcripts were compared by hierarchical clustering and correlation analysis, and response patterns were verified by reverse-transcription real-time polymerase chain reaction (RT-PCR). RESULTS Both xenoestrogens, BPA and HPTE, showed profiles highly correlated to that of E2 in the early response phase (2 hr), but the correlation diminished in the later response phase (24 hr), similar to the known weak estrogen E3. Both xenoestrogens also mimicked E2 in samples from KIKO mice, indicating that they are able to utilize the indirect tethering mode of ERα signaling. No response was detected in ERα-null uteri, indicating that ERα mediates the responses. CONCLUSION Our study forms a basis on which patterns of response and molecular mechanisms of potentially estrogenic chemicals can be assessed.
Collapse
Affiliation(s)
- Sylvia C Hewitt
- Receptor Biology Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA.
| | | |
Collapse
|
8
|
Hewitt SC, Kissling GE, Fieselman KE, Jayes FL, Gerrish KE, Korach KS. Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene. FASEB J 2010; 24:4660-7. [PMID: 20667977 DOI: 10.1096/fj.10-163428] [Citation(s) in RCA: 104] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
To address issues resulting from α estrogen receptor-knockout (αERKO) residual N-terminal truncated estrogen receptor α, and to allow tissue-selective deletion of ERα, we generated loxP-flanked exon 3 mice. Initial characterization of global sox2 cre-derived exon 3-deleted Ex3αERKO mice indicated no ERα protein in uterine tissue and recapitulation of previously described female phenotypes, confirming successful ablation of ERα. Body weights of Ex3αERKO female mice were 1.4-fold higher than wild-tupe (WT) females and comparable to WT males. Microarray indicated the Ex3αERKO uterus is free of residual estrogen responses. RT-PCR showed Nr4a1 is increased 41-fold by estrogen in WT and 7.4-fold in αERKO, and not increased in Ex3αERKO. Nr4a1, Cdkn1a, and c-fos transcripts were evaluated in WT and Ex3αERKO mice following estrogen, IGF1, or EGF injections. All 3 were increased by all treatments in WT. None were increased by estrogen in Ex3αERKO. Nr4a1 increased 24.5- and 14.7-fold, Cdkn1a increased 14.2- and 12.3-fold, and c-fos increased 20.9-fold and 16.2-fold after IGF1 and EGF treatments, respectively, in the Ex3αERKO mice, confirming that growth factor regulation is independent of ERα. Our Ex3α ERα model will be useful in studies of complete or selective ablation of ERα in target tissues.
Collapse
Affiliation(s)
- Sylvia C Hewitt
- Laboratory of Reproductive and Developmental Toxicology, National Institutes of Health, Research Triangle Park, North Carolina, USA.
| | | | | | | | | | | |
Collapse
|
9
|
Hewitt SC, Kissling GE, Fieselman KE, Jayes FL, Gerrish KE, Korach KS. Biological and biochemical consequences of global deletion of exon 3 from the ERα gene. FASEB J 2010. [DOI: 10.1096/fj.10.163428] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Sylvia C. Hewitt
- Laboratory of Reproductive and Developmental ToxicologyNational Institutes of Health, Research Triangle Park North Carolina USA
| | - Grace E. Kissling
- Biostatistics BranchNational Institutes of Health, Research Triangle Park North Carolina USA
| | - Karen E. Fieselman
- Laboratory of Reproductive and Developmental ToxicologyNational Institutes of Health, Research Triangle Park North Carolina USA
| | - Friederike L. Jayes
- Laboratory of Reproductive and Developmental ToxicologyNational Institutes of Health, Research Triangle Park North Carolina USA
| | - Kevin E. Gerrish
- Microarray Core National Institute of Environmental Health SciencesNational Institutes of Health, Research Triangle Park North Carolina USA
| | - Kenneth S. Korach
- Laboratory of Reproductive and Developmental ToxicologyNational Institutes of Health, Research Triangle Park North Carolina USA
| |
Collapse
|
10
|
Hewitt SC, Li Y, Li L, Korach KS. Estrogen-mediated regulation of Igf1 transcription and uterine growth involves direct binding of estrogen receptor alpha to estrogen-responsive elements. J Biol Chem 2010; 285:2676-85. [PMID: 19920132 PMCID: PMC2807324 DOI: 10.1074/jbc.m109.043471] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2009] [Revised: 11/16/2009] [Indexed: 12/20/2022] Open
Abstract
Estrogen enables uterine proliferation, which depends on synthesis of the IGF1 growth factor. This proliferation and IGF1 synthesis requires the estrogen receptor (ER), which binds directly to target DNA sequences (estrogen-responsive elements or EREs), or interacts with other transcription factors, such as AP1, to impact transcription. We observe neither uterine growth nor an increase in Igf1 transcript in a mouse with a DNA-binding mutated ER alpha (KIKO), indicating that both Igf1 regulation and uterine proliferation require the DNA binding function of the ER. We identified several potential EREs in the Igf1 gene, and chromatin immunoprecipitation analysis revealed ER alpha binding to these EREs in wild type but not KIKO chromatin. STAT5 is also reported to regulate Igf1; uterine Stat5a transcript is increased by estradiol (E(2)), but not in KIKO or alpha ERKO uteri, indicating ER alpha- and ERE-dependent regulation. ER alpha binds to a potential Stat5a ERE. We hypothesize that E(2) increases Stat5a transcript through ERE binding; that ER alpha, either alone or together with STAT5, then acts to increase Igf1 transcription; and that the resulting lack of IGF1 impairs KIKO uterine growth. Treatment with exogenous IGF1, alone or in combination with E(2), induces proliferation in wild type but not KIKO uteri, indicating that IGF1 replacement does not rescue the KIKO proliferative response. Together, these observations suggest in contrast to previous in vitro studies of IGF-1 regulation involving AP1 motifs that direct ER alpha-DNA interaction is required to increase Igf1 transcription. Additionally, full ER alpha function is needed to mediate other cellular signals of the growth factor for uterine growth.
Collapse
Affiliation(s)
- Sylvia C Hewitt
- Receptor Biology Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | |
Collapse
|
11
|
Action of estrogen on survival of basal forebrain cholinergic neurons: promoting amelioration. Psychoneuroendocrinology 2009; 34 Suppl 1:S104-12. [PMID: 19560872 DOI: 10.1016/j.psyneuen.2009.05.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2009] [Revised: 05/30/2009] [Accepted: 05/30/2009] [Indexed: 11/23/2022]
Abstract
Extensive studies during the past two decades provide compelling evidence that the gonadal steroid, estrogen, has the potential to affect the viability of basal forebrain cholinergic neurons. These observations reflect a unique ameliorative feature of estrogen as it restores and protects the cholinergic neurons against noxious stimuli or neurodegenerative processes. Hence, we first address the ameliorative function of estrogen on basal forebrain cholinergic neurons such as the actions of estrogen on neuronal plasticity of cholinergic neurons, estrogen-induced memory enhancement and the ameliorative role of estrogen on cholinergic neuron related neurodegenerative processes such as Alzheimer's disease. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of estrogen; influencing the amyloid precursor protein processing, enhancement in neurotrophin receptor signaling and estrogen-induced non-classical actions on second messenger systems. In addition, clinical relevance, pitfalls and future aspects of estrogen therapy on basal forebrain cholinergic neurons will be discussed.
Collapse
|
12
|
Hewitt SC, O'Brien JE, Jameson JL, Kissling GE, Korach KS. Selective disruption of ER{alpha} DNA-binding activity alters uterine responsiveness to estradiol. Mol Endocrinol 2009; 23:2111-6. [PMID: 19812388 DOI: 10.1210/me.2009-0356] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
In vitro models have been used to demonstrate that estrogen receptors (ERs) can regulate estrogen-responsive genes either by directly interacting with estrogen-responsive element (ERE) DNA motifs or by interacting with other transcription factors such as AP1. In this study, we evaluated estrogen (E(2))-dependent uterine gene profiles by microarray in the KIKO mouse, an in vivo knock-in mouse model that lacks the DNA-binding function of ERalpha and is consequently restricted to non-ERE-mediated responses. The 2- or 24-h E(2)-mediated uterine gene responses were distinct in wild-type (WT), KIKO, and alphaERKO genotypes, indicating that unique sets of genes are regulated by ERE and non-ERE pathways. After 2 h E(2) treatment, 38% of the WT transcripts were also regulated in the KIKO, demonstrating that the tethered mechanism does operate in this in vivo model. Surprisingly, 1438 E(2)-regulated transcripts were unique in the KIKO mouse and were not seen in either WT or alphaERKO. Pathway analyses revealed that some canonical pathways, such as the Jak/Stat pathway, were affected in a similar manner by E(2) in WT and KIKO. In other cases, however, the WT and KIKO differed. One example is the Wnt/beta-catenin pathway; this pathway was impacted, but different members of the pathway were regulated by E(2) or were regulated in a different manner, consistent with differences in biological responses. In summary, this study provides a comprehensive analysis of uterine genes regulated by E(2) via ERE and non-ERE pathways.
Collapse
Affiliation(s)
- Sylvia C Hewitt
- National Institute of Environment Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | |
Collapse
|
13
|
Pinto FM, Pintado CO, Pennefather JN, Patak E, Candenas L. Ovarian steroids regulate tachykinin and tachykinin receptor gene expression in the mouse uterus. Reprod Biol Endocrinol 2009; 7:77. [PMID: 19627578 PMCID: PMC2724541 DOI: 10.1186/1477-7827-7-77] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Accepted: 07/23/2009] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND In the mouse uterus, pregnancy is accompanied by changes in tachykinin and tachykinin receptor gene expression and in the uterotonic effects of endogenous tachykinins. In this study we have investigated whether changes in tachykinin expression and responses are a result of changes in ovarian steroid levels. METHODS We quantified the mRNAs of tachykinins and tachykinin receptors in uteri from ovariectomized mice and studied their regulation in response to estrogen and progesterone using real-time quantitative RT-PCR. Early (3 h) and late (24 h) responses to estrogen were evaluated and the participation of the estrogen receptors (ER), ERalpha and ERbeta, was analyzed by treating mice with propylpyrazole triol, a selective ERalpha agonist, or diarylpropionitrile, a selective agonist of ERbeta. RESULTS All genes encoding tachykinins (Tac1, Tac2 and Tac4) and tachykinin receptors (Tacr1, Tacr2 and Tacr3) were expressed in uteri from ovariectomized mice. Estrogen increased Tac1 and Tacr1 mRNA after 3 h and decreased Tac1 and Tac4 expression after 24 h. Tac2 and Tacr3 mRNA levels were decreased by estrogen at both 3 and 24 h. Most effects of estrogen were also observed in animals treated with propylpyrazole triol. Progesterone treatment increased the levels of Tac2. CONCLUSION These results show that the expression of tachykinins and their receptors in the mouse uterus is tightly and differentially regulated by ovarian steroids. Estrogen effects are mainly mediated by ERalpha supporting an essential role for this estrogen receptor in the regulation of the tachykinergic system in the mouse uterus.
Collapse
Affiliation(s)
- Francisco M Pinto
- Instituto de Investigaciones Químicas, CSIC, Avda. Americo Vespucio 49, 41092, Sevilla, Spain
| | - C Oscar Pintado
- Centro de Producción y Experimentación Animal, Universidad de Sevilla, Sevilla, Spain
| | - Jocelyn N Pennefather
- Department of Pharmaceutical Biology, Monash University, Parkville, Victoria 3052, Australia
| | - Eva Patak
- Department of Anaesthetics, Royal Women's Hospital, Carlton, Victoria 3051, Australia
| | - Luz Candenas
- Instituto de Investigaciones Químicas, CSIC, Avda. Americo Vespucio 49, 41092, Sevilla, Spain
| |
Collapse
|
14
|
Winuthayanon W, Piyachaturawat P, Suksamrarn A, Ponglikitmongkol M, Arao Y, Hewitt SC, Korach KS. Diarylheptanoid phytoestrogens isolated from the medicinal plant Curcuma comosa: biologic actions in vitro and in vivo indicate estrogen receptor-dependent mechanisms. ENVIRONMENTAL HEALTH PERSPECTIVES 2009; 117:1155-61. [PMID: 19654927 PMCID: PMC2717144 DOI: 10.1289/ehp.0900613] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2009] [Accepted: 03/23/2009] [Indexed: 05/23/2023]
Abstract
BACKGROUND Diarylheptanoids isolated from Curcuma comosa Roxb. have been recently identified as phyto estrogens. However, the mechanism underlying their actions has not yet been identified. OBJECTIVES We characterized the estrogenic activity of three active naturally occurring diarylheptanoids both in vitro and in vivo. METHODS We characterized mechanisms of estrogenic action of the diarylheptanoids (3S)-1,7-diphenyl-(6E)-6-hepten-3-ol (D1), 1,7-diphenyl-(6E)-6-hepten-3-one (D2), and (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol (D3) by using a real-time polymerase chain reaction assay, a mammalian transfection model, and a uterotrophic assay in mice. RESULTS All diarylheptanoids up-regulated estrogen-responsive genes in estrogen-responsive breast cancer cells (MCF-7). In HepG2 cells transfected with estrogen receptor (ER) beta or different ERalpha functional receptor mutants and the Vit-ERE-TATA-Luc reporter gene, all diarylheptanoids induced transcription through a ligand-dependent human ERalpha-ERE-driven pathway, which was abolished with ICI 182,780 (ER antagonist), whereas only D2 was active with ERbeta. An ERalpha mutant lacking the functional AF2 (activation function 2) region was not responsive to 17beta-estradiol (E(2)) or to any of the diarylheptanoids, whereas ERalpha lacking the AF1 domain exhibited wild-type-like activity. D3 markedly increased uterine weight and proliferation of the uterine epithelium in ovariectomized mice, whereas D1 and D2 were inactive. D3, like E(2), up-regulated lactoferrin (Ltf) gene expression. The responses to D3 in the uterus were inhibited by ICI 182,780. In addition, D3 stimulated both classical (Aqp5) and nonclassical (Cdkn1a) ER-mediated gene regulation. CONCLUSIONS The results suggest that the D3 diarylheptanoid is an agonist for ER both in vitro and in vivo, and its biological action is ERalpha selective, specifically requiring AF2 function, and involves direct binding via ER as well as ERE-independent gene regulation.
Collapse
MESH Headings
- Animals
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Curcuma/chemistry
- Diarylheptanoids/chemistry
- Diarylheptanoids/isolation & purification
- Diarylheptanoids/pharmacology
- Estradiol/analogs & derivatives
- Estradiol/pharmacology
- Estrogen Receptor alpha/antagonists & inhibitors
- Estrogen Receptor alpha/genetics
- Estrogen Receptor alpha/physiology
- Estrogen Receptor beta/antagonists & inhibitors
- Estrogen Receptor beta/genetics
- Estrogen Receptor beta/physiology
- Female
- Fulvestrant
- Humans
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Mutant Strains
- Organ Size/drug effects
- Ovariectomy
- Phytoestrogens/chemistry
- Phytoestrogens/isolation & purification
- Phytoestrogens/pharmacology
- Plant Extracts/chemistry
- Plant Extracts/isolation & purification
- Plant Extracts/pharmacology
- Plants, Medicinal/chemistry
- Polymerase Chain Reaction
- Receptors, Estrogen/antagonists & inhibitors
- Receptors, Estrogen/genetics
- Receptors, Estrogen/physiology
- Transcription, Genetic/drug effects
- Transcription, Genetic/genetics
- Uterus/cytology
- Uterus/drug effects
Collapse
Affiliation(s)
- Wipawee Winuthayanon
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand
- Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | | | - Apichart Suksamrarn
- Department of Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok, Thailand
| | | | - Yukitomo Arao
- Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | - Sylvia C. Hewitt
- Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| | - Kenneth S. Korach
- Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
| |
Collapse
|
15
|
Otto C, Fuchs I, Altmann H, Klewer M, Schwarz G, Bohlmann R, Nguyen D, Zorn L, Vonk R, Prelle K, Osterman T, Malmström C, Fritzemeier KH. In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro. J Steroid Biochem Mol Biol 2008; 111:95-100. [PMID: 18606537 DOI: 10.1016/j.jsbmb.2008.05.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2007] [Revised: 04/08/2008] [Accepted: 05/26/2008] [Indexed: 11/21/2022]
Abstract
Estrogen receptor (ER) ligands that are able to prevent postmenopausal bone loss, but have reduced activity in the uterus and the mammary gland might be of great value for hormone therapy. It is well established that the classical ER can activate genomic as well as nongenomic signal transduction pathways. In this study, we analyse the in vivo behaviour of ER ligands that stimulate nongenomic ER effects to the same extent as estradiol, but show clearly reduced activation of genomic ER effects in vitro. Using different readout parameters such as morphological changes, cellular proliferation, and target gene induction, we are able to demonstrate that ER ligands with reduced genomic activity in vitro show a better dissociation of bone versus uterine and mammary gland effects than estradiol that stimulates genomic and nongenomic effects to the same extent. We conclude that pathway-selective ER ligands may represent an interesting option for hormone therapy.
Collapse
Affiliation(s)
- Christiane Otto
- Research Laboratories, Bayer Schering Pharma AG, D-13353 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Manolagas SC, Jilka RL, Kousteni S, Bellido T, Weinstein RS, O'Brien CA, Plotkin L, Han L. Response to Windahl et al. J Clin Invest 2006; 116:2834. [PMID: 17080186 PMCID: PMC1626133 DOI: 10.1172/jci30535] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Kousteni S, Almeida M, Han L, Bellido T, Jilka RL, Manolagas SC. Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor. Mol Cell Biol 2006; 27:1516-30. [PMID: 17158928 PMCID: PMC1800724 DOI: 10.1128/mcb.01550-06] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Estrogens control gene transcription by cis or trans interactions of the estrogen receptor (ER) with target DNA or via the activation of cytoplasmic kinases. We report that selective activation of kinase-mediated actions of the ER with 4-estren-3alpha,17beta-diol (estren) or an estradiol-dendrimer conjugate, each a synthetic compound that stimulates kinase-mediated ER actions 1,000 to 10,000 times more potently than direct DNA interactions, induced osteoblastic differentiation in established cell lines of uncommitted osteoblast precursors and primary cultures of osteoblast progenitors by stimulating Wnt and BMP-2 signaling in a kinase-dependent manner. In sharp contrast, 17beta-estradiol (E(2)) suppressed BMP-2-induced osteoblast progenitor commitment and differentiation. Consistent with the in vitro findings, estren, but not E(2), stimulated Wnt/beta-catenin-mediated transcription in T-cell factor-lacZ transgenic mice. Moreover, E(2) stimulated BMP signaling in mice in which ERalpha lacks DNA binding activity and classical estrogen response element-mediated transcription (ERalpha(NERKI/-)) but not in wild-type controls. This evidence reveals for the first time the existence of a large signalosome in which inputs from the ER, kinases, bone morphogenetic proteins, and Wnt signaling converge to induce differentiation of osteoblast precursors. ER can either induce it or repress it, depending on whether the activating ligand (and presumably the resulting conformation of the receptor protein) precludes or accommodates ERE-mediated transcription.
Collapse
Affiliation(s)
- Stavroula Kousteni
- Division of Endocrinology and Metabolism, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
| | | | | | | | | | | |
Collapse
|
18
|
Windahl SH, Galien R, Chiusaroli R, Clément-Lacroix P, Morvan F, Lepescheux L, Nique F, Horne WC, Resche-Rigon M, Baron R. Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J Clin Invest 2006; 116:2500-9. [PMID: 16955145 PMCID: PMC1555662 DOI: 10.1172/jci28809] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2006] [Accepted: 06/20/2006] [Indexed: 11/17/2022] Open
Abstract
The use of estrogens and androgens to prevent bone loss is limited by their unwanted side effects, especially in reproductive organs and breast. Selective estrogen receptor modulators (SERMs) partially avoid such unwanted effects, but their efficacy on bone is only moderate compared with that of estradiol or androgens. Estrens have been suggested to not only prevent bone loss but also exert anabolic effects on bone while avoiding unwanted effects on reproductive organs. In this study, we compared the effects of a SERM (PSK3471) and 2 estrens (estren-alpha and estren-beta) on bone and reproductive organs to determine whether estrens are safe and act via the estrogen receptors and/or the androgen receptor (AR). Estrens and PSK3471 prevented gonadectomy-induced bone loss in male and female mice, but none showed true anabolic effects. Unlike SERMs, the estrens induced reproductive organ hypertrophy in both male and female mice and enhanced MCF-7 cell proliferation in vitro. Estrens directly activated transcription in several cell lines, albeit at much higher concentrations than estradiol or the SERM, and acted for the most part through the AR. We conclude that the estrens act mostly through the AR and, in mice, do not fulfill the preclinical efficacy or safety criteria required for the treatment or prevention of osteoporosis.
Collapse
Affiliation(s)
- Sara H. Windahl
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - René Galien
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Riccardo Chiusaroli
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Philippe Clément-Lacroix
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Frederic Morvan
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Liên Lepescheux
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - François Nique
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - William C. Horne
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Michèle Resche-Rigon
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Roland Baron
- Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
ProStrakan Pharmaceuticals, Romainville, France.
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
19
|
Abstract
Estrogens and androgens play a key role in regulating bone mass. However, their clinical use as bone anabolic agents is limited due to unwanted side effects, particularly in reproductive organs. In 2002, the synthetic ligand estren was described to reproduce the bone anabolic, nongenotropic effects of sex steroids while having no effect on the uterus or seminal vesicles. But in the current issue of the JCI, Windahl et al. provide data showing that estrens are not as suitable a replacement for estrogen as was initially reported (see the related article beginning on page 2500). Though not catabolic, estrens triggered only minor, nonsignificant increases in bone mass in gonadectomized mice, all the while inducing hypertrophy of reproductive organs. Does this mean estrens should not be pursued as a therapy for osteoporosis?
Collapse
Affiliation(s)
- Ushma S Neill
- Journal of Clinical Investigation, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
| |
Collapse
|
20
|
Abstract
For many decades, androgens have dominated endocrine research in hair growth control. Androgen metabolism and the androgen receptor currently are the key targets for systemic, pharmacological hair growth control in clinical medicine. However, it has long been known that estrogens also profoundly alter hair follicle growth and cycling by binding to locally expressed high-affinity estrogen receptors (ERs). Besides altering the transcription of genes with estrogen-responsive elements, 17beta-estradiol (E2) also modifies androgen metabolism within distinct subunits of the pilosebaceous unit (i.e., hair follicle and sebaceous gland). The latter displays prominent aromatase activity, the key enzyme for androgen conversion to E2, and is both an estrogen source and target. Here, we chart the recent renaissance of estrogen research in hair research; explain why the hair follicle offers an ideal, clinically relevant test system for studying the role of sex steroids, their receptors, and interactions in neuroectodermal-mesodermal interaction systems in general; and illustrate how it can be exploited to identify novel functions and signaling cross talks of ER-mediated signaling. Emphasizing the long-underestimated complexity and species-, gender-, and site-dependence of E2-induced biological effects on the hair follicle, we explore targets for pharmacological intervention in clinically relevant hair cycle manipulation, ranging from androgenetic alopecia and hirsutism via telogen effluvium to chemotherapy-induced alopecia. While defining major open questions, unsolved clinical challenges, and particularly promising research avenues in this area, we argue that the time has come to pay estrogen-mediated signaling the full attention it deserves in future endocrinological therapy of common hair growth disorders.
Collapse
Affiliation(s)
- Ulrich Ohnemus
- Department of Dermatology, University Hospital Schleswig-Holstein, Campus Lübeck, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
| | | | | | | | | |
Collapse
|